Breast Cancer Liquid Biopsy Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion
Loading…

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

Breast Cancer Liquid Biopsy Market Analysis — Presence

Geographical Analysis

Click countries to explore
Loading map…

Regional and Country Analysis

Region / Country 2021 (A)2025 (A)2033 (P) CAGR
Globalxxxxxxxxxxxx6.95%
North Americaxxxxxxxxxxxxxxxx
United Statesxxxxxxxxxxxxxxxx
Canadaxxxxxxxxxxxxxxxx
Mexicoxxxxxxxxxxxxxxxx
Europexxxxxxxxxxxxxxxx
United Kingdomxxxxxxxxxxxxxxxx
Francexxxxxxxxxxxxxxxx
Germanyxxxxxxxxxxxxxxxx
Italyxxxxxxxxxxxxxxxx
Russiaxxxxxxxxxxxxxxxx
Spainxxxxxxxxxxxxxxxx
Swedenxxxxxxxxxxxxxxxx
Denmarkxxxxxxxxxxxxxxxx
Switzerlandxxxxxxxxxxxxxxxx
Luxembourgxxxxxxxxxxxxxxxx
Rest of Europexxxxxxxxxxxxxxxx
Asia Pacificxxxxxxxxxxxxxxxx
Chinaxxxxxxxxxxxxxxxx
Japanxxxxxxxxxxxxxxxx
South Koreaxxxxxxxxxxxxxxxx
Indiaxxxxxxxxxxxxxxxx
Australiaxxxxxxxxxxxxxxxx
Singaporexxxxxxxxxxxxxxxx
Taiwanxxxxxxxxxxxxxxxx
South East Asiaxxxxxxxxxxxxxxxx
Rest of APACxxxxxxxxxxxxxxxx
South Americaxxxxxxxxxxxxxxxx
Brazilxxxxxxxxxxxxxxxx
Argentinaxxxxxxxxxxxxxxxx
Colombiaxxxxxxxxxxxxxxxx
Peruxxxxxxxxxxxxxxxx
Chilexxxxxxxxxxxxxxxx
Rest of South Americaxxxxxxxxxxxxxxxx
Middle Eastxxxxxxxxxxxxxxxx
Saudi Arabiaxxxxxxxxxxxxxxxx
Turkeyxxxxxxxxxxxxxxxx
UAExxxxxxxxxxxxxxxx
Egyptxxxxxxxxxxxxxxxx
Qatarxxxxxxxxxxxxxxxx
Rest of Middle Eastxxxxxxxxxxxxxxxx
Africaxxxxxxxxxxxxxxxx
East Africaxxxxxxxxxxxxxxxx
West Africaxxxxxxxxxxxxxxxx
North Africaxxxxxxxxxxxxxxxx
South Africaxxxxxxxxxxxxxxxx

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis


Market size by (Illustrative, 2025)
Share distribution (2025)

Charts are illustrative — exact values, country-level breakdowns, and full forecast in the paid report. Request a Free Sample PDF.

To learn more about market share and segmentation, request the free sample pages.

Competitor Analysis

Breast Cancer Liquid Biopsy Market News

  • March 2023

mDETECT Launched Breast Cancer Liquid Biopsy Clinical Trial

mDETECT Inc. a liquid biopsy company based on DNA methylation announced that Dr. Christopher Mueller, Professor at the Cancer Research Institute of Queen’s University and founder of mDETECT-Inc, was recently awarded a $900k grant from the Canadian Institute of Health Research (CIHR). 

  • August 2022

Liquid Biopsy Assay Expanded its offerings to Include MRD, Disease Recurrence Detection in Early-Stage Breast and Lung Cancer

The Guardant Reveal assay has been expanded for the detection of minimal residual disease (MRD) and disease recurrence in patients with early-stage breast cancer and lung cancer, according to an announcement from Guardant Health Inc.

Click any bar or cell to request the full company profile
Company2022 (A)2023 (A)2024 (A)2025 (A)
QIAGEN••• ••• ••• •••
NeoGenomics Laboratories••• ••• ••• •••
The Menarini Group••• ••• ••• •••
Biocept Inc.••• ••• ••• •••
F. Hoffmann-La Roche Ltd.••• ••• ••• •••
Sysmex Corporation••• ••• ••• •••
Epic Sciences Inc.••• ••• ••• •••
Myriad Genetics Inc.••• ••• ••• •••
Fluxion Biosciences Inc.••• ••• ••• •••
Illumina••• ••• ••• •••
Bio-Rad Laboratories••• ••• ••• •••
Myriad Genetics••• ••• ••• •••
Cynvenio••• ••• ••• •••
Biosystems Inc.••• ••• ••• •••
Genomic Health Inc.••• ••• ••• •••
Thermo Fisher Scientific Inc.••• ••• ••• •••
Fluxion Biosciences Inc.••• ••• ••• •••
Biodesix Inc.••• ••• ••• •••
Guardant Health Inc.••• ••• ••• •••
Isogen Life Science B.V.••• ••• ••• •••
others.••• ••• ••• •••

Revenue data requires full access. *2nd & 3rd tier companies available on enquiry.

Request company profile for validation →

Report Scope & Analysis

The global breast cancer liquid biopsy market was valued at USD 294.34 million in 2022 and is projected to reach USD 1481.65 million by 2030, registering a CAGR of 22.4% for the forecast period 2023- 2030.

Introduction of Breast Cancer Liquid Biopsy

Breast cancer liquid biopsy is a non-invasive diagnostic method for finding and examining breast cancer-related biomarkers in a patient's blood or other bodily fluids. It entails the gathering of a liquid sample, usually blood, and the examination of particular elements within that sample to find genetic mutations, changes, or other biomarkers connected to breast cancer. For breast cancer, circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) are the main targets of liquid biopsy studies. Cancer cells (CTCs) are cancer cells that have broken out from the original tumor and migrated into the circulation. Cancer cells that are on their way to dying leak pieces of their tumor DNA into the blood. These elements can reveal important details about the presence and traits of breast cancer.

Analyst Conclusion

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The Breast Cancer Liquid Biopsy Market Analysis is witnessing significant growth in the near future.

In 2023, the Circulating Tumor Cells (CTCs) segment accounted for a notable share of the Breast Cancer Liquid Biopsy Market Analysis.

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst at Cognitive Market Research · Cognitive Market Research
LinkedIn Profile Book Appointment

Frequently Asked Questions

Breast Cancer Liquid Biopsy Market Analysis market size and growth rate is provided in the report covering 2021-2025 historical and 2025-2033 forecast data.
Major factors including drivers, restraints, opportunities and challenges are analyzed with detailed insights.
Top manufacturers QIAGEN, NeoGenomics Laboratories, The Menarini Group, Biocept Inc., F. Hoffmann-La Roche Ltd., Sysmex Corporation, Epic Sciences Inc., Myriad Genetics Inc., Fluxion Biosciences Inc., Illumina, Bio-Rad Laboratories, Myriad Genetics, Cynvenio, Biosystems Inc., Genomic Health Inc., Thermo Fisher Scientific Inc., Fluxion Biosciences Inc., Biodesix Inc., Guardant Health Inc., Isogen Life Science B.V., others. and others are profiled in the report.
Segments include Circulating Biomarker, Application and additional sub-segments.
Regional analysis covers all major markets. The report identifies the dominant region and provides country-level data.
Sample pages can be obtained on demand from the website. 24/7 chat support and direct call services are available.

★ Reviews

Rate this report

Breast Cancer Liquid Biopsy Market Analysis — Table of Contents

Disclaimer:
  • This is just a redacted sample pages of the actual deliverable report and only for representative purposes
  • Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
  • The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
  • Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
  • If applicable; On Request Volume Data will also be provided (at an Additional Cost).
License Edition

Circulating Biomarker Circulating Tumor Cells (CTCs), Cell-free DNA (cfDNA), Extracellular Vesicles (EVs), Other
Application Reference Laboratories, Hospitals and Physician Laboratories, Other
List of Competitors QIAGEN, NeoGenomics Laboratories, The Menarini Group, Biocept Inc., F. Hoffmann-La Roche Ltd., Sysmex Corporation, Epic Sciences Inc., Myriad Genetics Inc., Fluxion Biosciences Inc., Illumina, Bio-Rad Laboratories, Myriad Genetics, Cynvenio, Biosystems Inc., Genomic Health Inc., Thermo Fisher Scientific Inc., Fluxion Biosciences Inc., Biodesix Inc., Guardant Health Inc., Isogen Life Science B.V., others.

  • 1.1 Global Breast Cancer Liquid Biopsy Revenue Market Size, Trend Analysis 2022 - 2034
  • 1.2 Global Breast Cancer Liquid Biopsy Volume Market Sales, Trend Analysis 2022 - 2034

  • Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.

    1.3 Global Breast Cancer Liquid Biopsy Market Size By Regions 2022 - 2034
    • 1.3.1 Global Breast Cancer Liquid Biopsy Revenue Market Size By Region
    • 1.3.2 Global Breast Cancer Liquid Biopsy Volume Market Sales By Region
  • 1.4 Global Breast Cancer Liquid Biopsy Market Size By Circulating Biomarker 2022 - 2034
    • 1.4.1 Circulating Tumor Cells (CTCs) Market Size
    • 1.4.2 Cell-free DNA (cfDNA) Market Size
    • 1.4.3 Extracellular Vesicles (EVs) Market Size
    • 1.4.4 Other Market Size
  • 1.5 Global Breast Cancer Liquid Biopsy Volume Market Sales By Circulating Biomarker 2022 - 2034
    • 1.5.1 Circulating Tumor Cells (CTCs) Sales Volume
    • 1.5.2 Cell-free DNA (cfDNA) Sales Volume
    • 1.5.3 Extracellular Vesicles (EVs) Sales Volume
    • 1.5.4 Other Sales Volume
  • 1.6 Global Breast Cancer Liquid Biopsy Market Size By Application 2022 - 2034
    • 1.6.1 Reference Laboratories Market Size
    • 1.6.2 Hospitals and Physician Laboratories Market Size
    • 1.6.3 Other Market Size
  • 1.7 Global Breast Cancer Liquid Biopsy Volume Market Sales By Application 2022 - 2034
    • 1.7.1 Reference Laboratories Sales Volume
    • 1.7.2 Hospitals and Physician Laboratories Sales Volume
    • 1.7.3 Other Sales Volume
  • 1.8 Global Level Competitor Analysis (Subject to Data Availability (Private Players))

  • You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)

    1.9 Executive Summary Global Market (2021 vs 2025 vs 2033)
    • 1.9.1 Regional Market Revenue Summary 2021 vs 2025 vs 2033
    • 1.9.2 Regional Volume Market Summary 2021 vs 2025 vs 2033
    • 1.9.3 Global Market Revenue Split By Circulating Biomarker
    • 1.9.4 Global Volume Market Split By Circulating Biomarker
    • 1.9.5 Global Market Revenue Split By Application
    • 1.9.6 Global Volume Market Split By Application

    • Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable

      1.9.7 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities

  • 2.1 North America Breast Cancer Liquid Biopsy Market Outlook
    • 2.1.1 North America Breast Cancer Liquid Biopsy Market Size 2022 - 2034
    • 2.1.2 North America Breast Cancer Liquid Biopsy Volume Market Sales 2022 - 2034
    • 2.1.3 North America Breast Cancer Liquid Biopsy Market Size By Country 2022 - 2034
    • 2.1.4 North America Breast Cancer Liquid Biopsy Volume Market Sales By Country 2022 - 2034
    • 2.1.5 North America Breast Cancer Liquid Biopsy Market Size by Circulating Biomarker 2022 - 2034
      • 2.1.5.1 North America Circulating Tumor Cells (CTCs) Market Size
      • 2.1.5.2 North America Cell-free DNA (cfDNA) Market Size
      • 2.1.5.3 North America Extracellular Vesicles (EVs) Market Size
      • 2.1.5.4 North America Other Market Size
    • 2.1.6 North America Breast Cancer Liquid Biopsy Volume Market Sales by Circulating Biomarker 2022 - 2034
      • 2.1.6.1 North America Circulating Tumor Cells (CTCs) Sales Volume
      • 2.1.6.2 North America Cell-free DNA (cfDNA) Sales Volume
      • 2.1.6.3 North America Extracellular Vesicles (EVs) Sales Volume
      • 2.1.6.4 North America Other Sales Volume
    • 2.1.7 North America Breast Cancer Liquid Biopsy Market Size by Application 2022 - 2034
      • 2.1.7.1 North America Reference Laboratories Market Size
      • 2.1.7.2 North America Hospitals and Physician Laboratories Market Size
      • 2.1.7.3 North America Other Market Size
    • 2.1.8 North America Breast Cancer Liquid Biopsy Volume Market Sales by Application 2022 - 2034
      • 2.1.8.1 North America Reference Laboratories Sales Volume
      • 2.1.8.2 North America Hospitals and Physician Laboratories Sales Volume
      • 2.1.8.3 North America Other Sales Volume

  • 3.1 Europe Breast Cancer Liquid Biopsy Market Outlook
    • 3.1.1 Europe Breast Cancer Liquid Biopsy Market Size 2022 - 2034
    • 3.1.2 Europe Breast Cancer Liquid Biopsy Volume Market Sales 2022 - 2034
    • 3.1.3 Europe Breast Cancer Liquid Biopsy Market Size By Country 2022 - 2034
    • 3.1.4 Europe Breast Cancer Liquid Biopsy Volume Market Sales By Country 2022 - 2034
    • 3.1.5 Europe Breast Cancer Liquid Biopsy Market Size by Circulating Biomarker 2022 - 2034
      • 3.1.5.1 Europe Circulating Tumor Cells (CTCs) Market Size
      • 3.1.5.2 Europe Cell-free DNA (cfDNA) Market Size
      • 3.1.5.3 Europe Extracellular Vesicles (EVs) Market Size
      • 3.1.5.4 Europe Other Market Size
    • 3.1.6 Europe Breast Cancer Liquid Biopsy Volume Market Sales by Circulating Biomarker 2022 - 2034
      • 3.1.6.1 Europe Circulating Tumor Cells (CTCs) Sales Volume
      • 3.1.6.2 Europe Cell-free DNA (cfDNA) Sales Volume
      • 3.1.6.3 Europe Extracellular Vesicles (EVs) Sales Volume
      • 3.1.6.4 Europe Other Sales Volume
    • 3.1.7 Europe Breast Cancer Liquid Biopsy Market Size by Application 2022 - 2034
      • 3.1.7.1 Europe Reference Laboratories Market Size
      • 3.1.7.2 Europe Hospitals and Physician Laboratories Market Size
      • 3.1.7.3 Europe Other Market Size
    • 3.1.8 Europe Breast Cancer Liquid Biopsy Volume Market Sales by Application 2022 - 2034
      • 3.1.8.1 Europe Reference Laboratories Sales Volume
      • 3.1.8.2 Europe Hospitals and Physician Laboratories Sales Volume
      • 3.1.8.3 Europe Other Sales Volume

  • 4.1 Asia Pacific Breast Cancer Liquid Biopsy Market Outlook
    • 4.1.1 Asia Pacific Breast Cancer Liquid Biopsy Market Size 2022 - 2034
    • 4.1.2 Asia Pacific Breast Cancer Liquid Biopsy Volume Market Sales 2022 - 2034
    • 4.1.3 Asia Pacific Breast Cancer Liquid Biopsy Market Size By Country 2022 - 2034
    • 4.1.4 Asia Pacific Breast Cancer Liquid Biopsy Volume Market Sales By Country 2022 - 2034
    • 4.1.5 Asia Pacific Breast Cancer Liquid Biopsy Market Size by Circulating Biomarker 2022 - 2034
      • 4.1.5.1 Asia Pacific Circulating Tumor Cells (CTCs) Market Size
      • 4.1.5.2 Asia Pacific Cell-free DNA (cfDNA) Market Size
      • 4.1.5.3 Asia Pacific Extracellular Vesicles (EVs) Market Size
      • 4.1.5.4 Asia Pacific Other Market Size
    • 4.1.6 Asia Pacific Breast Cancer Liquid Biopsy Volume Market Sales by Circulating Biomarker 2022 - 2034
      • 4.1.6.1 Asia Pacific Circulating Tumor Cells (CTCs) Sales Volume
      • 4.1.6.2 Asia Pacific Cell-free DNA (cfDNA) Sales Volume
      • 4.1.6.3 Asia Pacific Extracellular Vesicles (EVs) Sales Volume
      • 4.1.6.4 Asia Pacific Other Sales Volume
    • 4.1.7 Asia Pacific Breast Cancer Liquid Biopsy Market Size by Application 2022 - 2034
      • 4.1.7.1 Asia Pacific Reference Laboratories Market Size
      • 4.1.7.2 Asia Pacific Hospitals and Physician Laboratories Market Size
      • 4.1.7.3 Asia Pacific Other Market Size
    • 4.1.8 Asia Pacific Breast Cancer Liquid Biopsy Volume Market Sales by Application 2022 - 2034
      • 4.1.8.1 Asia Pacific Reference Laboratories Sales Volume
      • 4.1.8.2 Asia Pacific Hospitals and Physician Laboratories Sales Volume
      • 4.1.8.3 Asia Pacific Other Sales Volume

  • 5.1 South America Breast Cancer Liquid Biopsy Market Outlook
    • 5.1.1 South America Breast Cancer Liquid Biopsy Market Size 2022 - 2034
    • 5.1.2 South America Breast Cancer Liquid Biopsy Volume Market Sales 2022 - 2034
    • 5.1.3 South America Breast Cancer Liquid Biopsy Market Size By Country 2022 - 2034
    • 5.1.4 South America Breast Cancer Liquid Biopsy Volume Market Sales By Country 2022 - 2034
    • 5.1.5 South America Breast Cancer Liquid Biopsy Market Size by Circulating Biomarker 2022 - 2034
      • 5.1.5.1 South America Circulating Tumor Cells (CTCs) Market Size
      • 5.1.5.2 South America Cell-free DNA (cfDNA) Market Size
      • 5.1.5.3 South America Extracellular Vesicles (EVs) Market Size
      • 5.1.5.4 South America Other Market Size
    • 5.1.6 South America Breast Cancer Liquid Biopsy Volume Market Sales by Circulating Biomarker 2022 - 2034
      • 5.1.6.1 South America Circulating Tumor Cells (CTCs) Sales Volume
      • 5.1.6.2 South America Cell-free DNA (cfDNA) Sales Volume
      • 5.1.6.3 South America Extracellular Vesicles (EVs) Sales Volume
      • 5.1.6.4 South America Other Sales Volume
    • 5.1.7 South America Breast Cancer Liquid Biopsy Market Size by Application 2022 - 2034
      • 5.1.7.1 South America Reference Laboratories Market Size
      • 5.1.7.2 South America Hospitals and Physician Laboratories Market Size
      • 5.1.7.3 South America Other Market Size
    • 5.1.8 South America Breast Cancer Liquid Biopsy Volume Market Sales by Application 2022 - 2034
      • 5.1.8.1 South America Reference Laboratories Sales Volume
      • 5.1.8.2 South America Hospitals and Physician Laboratories Sales Volume
      • 5.1.8.3 South America Other Sales Volume

  • 6.1 Middle East Breast Cancer Liquid Biopsy Market Outlook
    • 6.1.1 Middle East Breast Cancer Liquid Biopsy Market Size 2022 - 2034
    • 6.1.2 Middle East Breast Cancer Liquid Biopsy Volume Market Sales 2022 - 2034
    • 6.1.3 Middle East Breast Cancer Liquid Biopsy Market Size By Country 2022 - 2034
    • 6.1.4 Middle East Breast Cancer Liquid Biopsy Volume Market Sales By Country 2022 - 2034
    • 6.1.5 Middle East Breast Cancer Liquid Biopsy Market Size by Circulating Biomarker 2022 - 2034
      • 6.1.5.1 Middle East Circulating Tumor Cells (CTCs) Market Size
      • 6.1.5.2 Middle East Cell-free DNA (cfDNA) Market Size
      • 6.1.5.3 Middle East Extracellular Vesicles (EVs) Market Size
      • 6.1.5.4 Middle East Other Market Size
    • 6.1.6 Middle East Breast Cancer Liquid Biopsy Volume Market Sales by Circulating Biomarker 2022 - 2034
      • 6.1.6.1 Middle East Circulating Tumor Cells (CTCs) Sales Volume
      • 6.1.6.2 Middle East Cell-free DNA (cfDNA) Sales Volume
      • 6.1.6.3 Middle East Extracellular Vesicles (EVs) Sales Volume
      • 6.1.6.4 Middle East Other Sales Volume
    • 6.1.7 Middle East Breast Cancer Liquid Biopsy Market Size by Application 2022 - 2034
      • 6.1.7.1 Middle East Reference Laboratories Market Size
      • 6.1.7.2 Middle East Hospitals and Physician Laboratories Market Size
      • 6.1.7.3 Middle East Other Market Size
    • 6.1.8 Middle East Breast Cancer Liquid Biopsy Volume Market Sales by Application 2022 - 2034
      • 6.1.8.1 Middle East Reference Laboratories Sales Volume
      • 6.1.8.2 Middle East Hospitals and Physician Laboratories Sales Volume
      • 6.1.8.3 Middle East Other Sales Volume

  • 7.1 Africa Breast Cancer Liquid Biopsy Market Outlook
    • 7.1.1 Africa Breast Cancer Liquid Biopsy Market Size 2022 - 2034
    • 7.1.2 Africa Breast Cancer Liquid Biopsy Volume Market Sales 2022 - 2034
    • 7.1.3 Africa Breast Cancer Liquid Biopsy Market Size By Country 2022 - 2034
    • 7.1.4 Africa Breast Cancer Liquid Biopsy Volume Market Sales By Country 2022 - 2034
    • 7.1.5 Africa Breast Cancer Liquid Biopsy Market Size by Circulating Biomarker 2022 - 2034
      • 7.1.5.1 Africa Circulating Tumor Cells (CTCs) Market Size
      • 7.1.5.2 Africa Cell-free DNA (cfDNA) Market Size
      • 7.1.5.3 Africa Extracellular Vesicles (EVs) Market Size
      • 7.1.5.4 Africa Other Market Size
    • 7.1.6 Africa Breast Cancer Liquid Biopsy Volume Market Sales by Circulating Biomarker 2022 - 2034
      • 7.1.6.1 Africa Circulating Tumor Cells (CTCs) Sales Volume
      • 7.1.6.2 Africa Cell-free DNA (cfDNA) Sales Volume
      • 7.1.6.3 Africa Extracellular Vesicles (EVs) Sales Volume
      • 7.1.6.4 Africa Other Sales Volume
    • 7.1.7 Africa Breast Cancer Liquid Biopsy Market Size by Application 2022 - 2034
      • 7.1.7.1 Africa Reference Laboratories Market Size
      • 7.1.7.2 Africa Hospitals and Physician Laboratories Market Size
      • 7.1.7.3 Africa Other Market Size
    • 7.1.8 Africa Breast Cancer Liquid Biopsy Volume Market Sales by Application 2022 - 2034
      • 7.1.8.1 Africa Reference Laboratories Sales Volume
      • 7.1.8.2 Africa Hospitals and Physician Laboratories Sales Volume
      • 7.1.8.3 Africa Other Sales Volume

  • 8.1 Top Competitors Analysis

    • (Subject to Data Availability (Private Players))

      8.1.1 Global Breast Cancer Liquid Biopsy Market Analysis by Key Players
    • 8.1.2 Global Breast Cancer Liquid Biopsy Market Volume and Share by Key Players
    • 8.1.3 Top Players Ranking 2024
    • 8.1.4 New Product Launch Analysis
    • 8.1.5 Industry Mergers and Acquisition Analysis
  • 8.2 Company Profile (Data Subject to Availability) Sample Format

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.1 QIAGEN
      • 8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.1.2 Business Overview
      • 8.2.1.3 Financials (Subject to data availability)
      • 8.2.1.4 R&D Investment (Subject to data availability)
      • 8.2.1.5 Product Types Specification
      • 8.2.1.6 Business Strategy
      • 8.2.1.7 Recent Developments
      • 8.2.1.8 Management Change
      • 8.2.1.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.2 NeoGenomics Laboratories
      • 8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.2.2 Business Overview
      • 8.2.2.3 Financials (Subject to data availability)
      • 8.2.2.4 R&D Investment (Subject to data availability)
      • 8.2.2.5 Product Types Specification
      • 8.2.2.6 Business Strategy
      • 8.2.2.7 Recent Developments
      • 8.2.2.8 Management Change
      • 8.2.2.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.3 The Menarini Group
      • 8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.3.2 Business Overview
      • 8.2.3.3 Financials (Subject to data availability)
      • 8.2.3.4 R&D Investment (Subject to data availability)
      • 8.2.3.5 Product Types Specification
      • 8.2.3.6 Business Strategy
      • 8.2.3.7 Recent Developments
      • 8.2.3.8 Management Change
      • 8.2.3.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.4 Biocept Inc.
      • 8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.4.2 Business Overview
      • 8.2.4.3 Financials (Subject to data availability)
      • 8.2.4.4 R&D Investment (Subject to data availability)
      • 8.2.4.5 Product Types Specification
      • 8.2.4.6 Business Strategy
      • 8.2.4.7 Recent Developments
      • 8.2.4.8 Management Change
      • 8.2.4.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.5 F. Hoffmann-La Roche Ltd.
      • 8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.5.2 Business Overview
      • 8.2.5.3 Financials (Subject to data availability)
      • 8.2.5.4 R&D Investment (Subject to data availability)
      • 8.2.5.5 Product Types Specification
      • 8.2.5.6 Business Strategy
      • 8.2.5.7 Recent Developments
      • 8.2.5.8 Management Change
      • 8.2.5.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.6 Sysmex Corporation
      • 8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.6.2 Business Overview
      • 8.2.6.3 Financials (Subject to data availability)
      • 8.2.6.4 R&D Investment (Subject to data availability)
      • 8.2.6.5 Product Types Specification
      • 8.2.6.6 Business Strategy
      • 8.2.6.7 Recent Developments
      • 8.2.6.8 Management Change
      • 8.2.6.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.7 Epic Sciences Inc.
      • 8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.7.2 Business Overview
      • 8.2.7.3 Financials (Subject to data availability)
      • 8.2.7.4 R&D Investment (Subject to data availability)
      • 8.2.7.5 Product Types Specification
      • 8.2.7.6 Business Strategy
      • 8.2.7.7 Recent Developments
      • 8.2.7.8 Management Change
      • 8.2.7.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.8 Myriad Genetics Inc.
      • 8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.8.2 Business Overview
      • 8.2.8.3 Financials (Subject to data availability)
      • 8.2.8.4 R&D Investment (Subject to data availability)
      • 8.2.8.5 Product Types Specification
      • 8.2.8.6 Business Strategy
      • 8.2.8.7 Recent Developments
      • 8.2.8.8 Management Change
      • 8.2.8.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.9 Fluxion Biosciences Inc.
      • 8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.9.2 Business Overview
      • 8.2.9.3 Financials (Subject to data availability)
      • 8.2.9.4 R&D Investment (Subject to data availability)
      • 8.2.9.5 Product Types Specification
      • 8.2.9.6 Business Strategy
      • 8.2.9.7 Recent Developments
      • 8.2.9.8 Management Change
      • 8.2.9.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.10 Illumina
      • 8.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.10.2 Business Overview
      • 8.2.10.3 Financials (Subject to data availability)
      • 8.2.10.4 R&D Investment (Subject to data availability)
      • 8.2.10.5 Product Types Specification
      • 8.2.10.6 Business Strategy
      • 8.2.10.7 Recent Developments
      • 8.2.10.8 Management Change
      • 8.2.10.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.11 Bio-Rad Laboratories
      • 8.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.11.2 Business Overview
      • 8.2.11.3 Financials (Subject to data availability)
      • 8.2.11.4 R&D Investment (Subject to data availability)
      • 8.2.11.5 Product Types Specification
      • 8.2.11.6 Business Strategy
      • 8.2.11.7 Recent Developments
      • 8.2.11.8 Management Change
      • 8.2.11.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.12 Myriad Genetics
      • 8.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.12.2 Business Overview
      • 8.2.12.3 Financials (Subject to data availability)
      • 8.2.12.4 R&D Investment (Subject to data availability)
      • 8.2.12.5 Product Types Specification
      • 8.2.12.6 Business Strategy
      • 8.2.12.7 Recent Developments
      • 8.2.12.8 Management Change
      • 8.2.12.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.13 Cynvenio
      • 8.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.13.2 Business Overview
      • 8.2.13.3 Financials (Subject to data availability)
      • 8.2.13.4 R&D Investment (Subject to data availability)
      • 8.2.13.5 Product Types Specification
      • 8.2.13.6 Business Strategy
      • 8.2.13.7 Recent Developments
      • 8.2.13.8 Management Change
      • 8.2.13.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.14 Biosystems Inc.
      • 8.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.14.2 Business Overview
      • 8.2.14.3 Financials (Subject to data availability)
      • 8.2.14.4 R&D Investment (Subject to data availability)
      • 8.2.14.5 Product Types Specification
      • 8.2.14.6 Business Strategy
      • 8.2.14.7 Recent Developments
      • 8.2.14.8 Management Change
      • 8.2.14.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.15 Genomic Health Inc.
      • 8.2.15.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.15.2 Business Overview
      • 8.2.15.3 Financials (Subject to data availability)
      • 8.2.15.4 R&D Investment (Subject to data availability)
      • 8.2.15.5 Product Types Specification
      • 8.2.15.6 Business Strategy
      • 8.2.15.7 Recent Developments
      • 8.2.15.8 Management Change
      • 8.2.15.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.16 Thermo Fisher Scientific Inc.
      • 8.2.16.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.16.2 Business Overview
      • 8.2.16.3 Financials (Subject to data availability)
      • 8.2.16.4 R&D Investment (Subject to data availability)
      • 8.2.16.5 Product Types Specification
      • 8.2.16.6 Business Strategy
      • 8.2.16.7 Recent Developments
      • 8.2.16.8 Management Change
      • 8.2.16.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.17 Fluxion Biosciences Inc.
      • 8.2.17.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.17.2 Business Overview
      • 8.2.17.3 Financials (Subject to data availability)
      • 8.2.17.4 R&D Investment (Subject to data availability)
      • 8.2.17.5 Product Types Specification
      • 8.2.17.6 Business Strategy
      • 8.2.17.7 Recent Developments
      • 8.2.17.8 Management Change
      • 8.2.17.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.18 Biodesix Inc.
      • 8.2.18.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.18.2 Business Overview
      • 8.2.18.3 Financials (Subject to data availability)
      • 8.2.18.4 R&D Investment (Subject to data availability)
      • 8.2.18.5 Product Types Specification
      • 8.2.18.6 Business Strategy
      • 8.2.18.7 Recent Developments
      • 8.2.18.8 Management Change
      • 8.2.18.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.19 Guardant Health Inc.
      • 8.2.19.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.19.2 Business Overview
      • 8.2.19.3 Financials (Subject to data availability)
      • 8.2.19.4 R&D Investment (Subject to data availability)
      • 8.2.19.5 Product Types Specification
      • 8.2.19.6 Business Strategy
      • 8.2.19.7 Recent Developments
      • 8.2.19.8 Management Change
      • 8.2.19.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.20 Isogen Life Science B.V.
      • 8.2.20.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.20.2 Business Overview
      • 8.2.20.3 Financials (Subject to data availability)
      • 8.2.20.4 R&D Investment (Subject to data availability)
      • 8.2.20.5 Product Types Specification
      • 8.2.20.6 Business Strategy
      • 8.2.20.7 Recent Developments
      • 8.2.20.8 Management Change
      • 8.2.20.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      8.2.21 others.
      • 8.2.21.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 8.2.21.2 Business Overview
      • 8.2.21.3 Financials (Subject to data availability)
      • 8.2.21.4 R&D Investment (Subject to data availability)
      • 8.2.21.5 Product Types Specification
      • 8.2.21.6 Business Strategy
      • 8.2.21.7 Recent Developments
      • 8.2.21.8 Management Change
      • 8.2.21.9 S.W.O.T Analysis

  • 9.1 Market Drivers
  • 9.2 Market Restraints
  • 9.3 Market Trends
  • 9.4 Market Opportunity
  • 9.5 Technological Road Map (Subject to Data Availability)
  • 9.6 Product Life Cycle (Subject to Data Availability)
  • 9.7 Customer and Buyer Behavior Analysis
    • 9.7.1 Consumer Demographics and Target Audience Assessment
    • 9.7.2 Consumer Purchase Behavior and Demand Assessment
    • 9.7.3 Consumer Pricing Dynamics and Affordability Assessment
    • 9.7.4 Digital Consumer Engagement and Online Adoption Analysis
    • 9.7.5 Future Consumption Trends and Demand Evolution Analysis
    • 9.7.6 Enterprise Procurement & Purchasing Behavior Analysis
    • 9.7.7 Buyer Decision-Making & Purchase Influence Assessment
    • 9.7.8 Customer Expectations & Service Experience Evaluation
    • 9.7.9 Vendor Selection & Supplier Preference Analysis
    • 9.7.10 Customer Retention & Loyalty Strategy Assessment
    • 9.7.11 Pricing Sensitivity & Value Perception Analysis
    • 9.7.12 Customer Segmentation & Demand Pattern Analysis
    • 9.7.13 Relationship Management & Strategic Partnership Trends
  • 9.8 Market Attractiveness Analysis
  • 9.9 PESTEL Analysis
    • 9.9.1 Political Factors
    • 9.9.2 Economic Factors
    • 9.9.3 Social Factors
    • 9.9.4 Technological Factors
    • 9.9.5 Legal Factors
    • 9.9.6 Environmental Factors
  • 9.10 Industrial Chain Analysis (Subject to Data Availability)
    • 9.10.1 Industry Chain Analysis
    • 9.10.2 Manufacturing Cost Analysis
    • 9.10.3 Supply Side Analysis
      • 9.10.3.1 Raw Material Analysis
      • 9.10.3.2 Raw Material Procurement Analysis
      • 9.10.3.3 Raw Material Price Trend Analysis
  • 9.11 Porter’s Five Forces Analysis
    • 9.11.1 Bargaining Power of Suppliers
    • 9.11.2 Bargaining Power of Buyers
    • 9.11.3 Threat of New Entrants
    • 9.11.4 Threat of Substitutes
    • 9.11.5 Degree of Competition
  • 9.12 Patent Analysis (Subject to Data Availability)
  • 9.13 ESG Analysis
  • 9.14 Geopolitical Outlook
    • 9.14.1 Global Power Realignment & Strategic Alliances
    • 9.14.2 Geopolitical Risk Landscape & Conflict Hotspots
    • 9.14.3 International Trade Relations & Market Access Environment
    • 9.14.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
    • 9.14.5 Supply Chain Resilience, Localization & Resource Nationalism
    • 9.14.6 Technology Sovereignty & Digital Geopolitics
    • 9.14.7 Strategic Implications for Investment, Growth & Market Entry

  • This chapter isn't just about technology; it’s about certainty. We show you how AI is being used in leading industries so you can apply those same 'High-Speed' and 'High-Accuracy' principles to your own market strategy

    9.15 AI & Market Transformation
    • 9.15.1 Competitive Landscape Disruption & Strategic Shifts
    • 9.15.2 AI-Driven Transformation of Industry Value Chain
    • 9.15.3 Evolution of Business Models & Revenue Streams
    • 9.15.4 Operational Efficiency & Cost Structure Transformation
    • 9.15.5 Product, Service & Innovation Acceleration
    • 9.15.6 Customer Behavior & Demand Evolution
    • 9.15.7 Future Outlook: AI-Led Market Evolution & Strategic Implications

  • 10.1 Circulating Tumor Cells (CTCs)
    • 10.1.1 Global Breast Cancer Liquid Biopsy Revenue Market Size and Share by Circulating Tumor Cells (CTCs) 2022 - 2034
    • 10.1.2 Global Breast Cancer Liquid Biopsy Volume Market Sales by Circulating Tumor Cells (CTCs) 2022 - 2034
  • 10.2 Cell-free DNA (cfDNA)
    • 10.2.1 Global Breast Cancer Liquid Biopsy Revenue Market Size and Share by Cell-free DNA (cfDNA) 2022 - 2034
    • 10.2.2 Global Breast Cancer Liquid Biopsy Volume Market Sales by Cell-free DNA (cfDNA) 2022 - 2034
  • 10.3 Extracellular Vesicles (EVs)
    • 10.3.1 Global Breast Cancer Liquid Biopsy Revenue Market Size and Share by Extracellular Vesicles (EVs) 2022 - 2034
    • 10.3.2 Global Breast Cancer Liquid Biopsy Volume Market Sales by Extracellular Vesicles (EVs) 2022 - 2034
  • 10.4 Other
    • 10.4.1 Global Breast Cancer Liquid Biopsy Revenue Market Size and Share by Other 2022 - 2034
    • 10.4.2 Global Breast Cancer Liquid Biopsy Volume Market Sales by Other 2022 - 2034

  • 11.1 Reference Laboratories
    • 11.1.1 Global Breast Cancer Liquid Biopsy Revenue Market Size and Share by Reference Laboratories 2022 - 2034
    • 11.1.2 Global Breast Cancer Liquid Biopsy Volume Market Sales by Reference Laboratories 2022 - 2034
  • 11.2 Hospitals and Physician Laboratories
    • 11.2.1 Global Breast Cancer Liquid Biopsy Revenue Market Size and Share by Hospitals and Physician Laboratories 2022 - 2034
    • 11.2.2 Global Breast Cancer Liquid Biopsy Volume Market Sales by Hospitals and Physician Laboratories 2022 - 2034
  • 11.3 Other
    • 11.3.1 Global Breast Cancer Liquid Biopsy Revenue Market Size and Share by Other 2022 - 2034
    • 11.3.2 Global Breast Cancer Liquid Biopsy Volume Market Sales by Other 2022 - 2034

  • 12.1 Company Gap Assessment Analysis
  • 12.2 Product & Service Portfolio Gap Analysis
  • 12.3 Demand-Supply Imbalance Analysis
  • 12.4 Market Opportunity & Unmet Needs Analysis
  • 12.5 Technology Adoption & Digital Transformation Gap Analysis
  • 12.6 Operational Efficiency & Process Gap Analysis
  • 12.7 Infrastructure & Capacity Gap Analysis
  • 12.8 Geographic Coverage & Distribution Gap Analysis
  • 12.9 Investment Opportunity & Funding Gap Analysis
  • 12.10 Pricing Structure & Margin Gap Analysis
  • 12.11 Innovation & R&D Capability Gap Analysis
  • 12.12 Policy, Compliance & Regulatory Gap Analysis
  • 12.13 Customer Experience & Expectation Gap Analysis
  • 12.14 Future Growth Opportunity Gap Analysis
  • 12.15 Market Accessibility & Penetration Gap Analysis

  • 13.1 Gross Margin Overview and Industry Profitability Trends
  • 13.2 Regional Gross Margin Performance Analysis
  • 13.3 Supply Chain and Distribution Impact on Gross Margins
  • 13.4 Pricing Strategy and Value-Added Margin Assessment
  • 13.5 Key Factors Influencing Gross Margin Variability
  • 13.6 Future Gross Margin Outlook and Profitability Trends

  • 14.1 Key Takeaways

  • Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.

    14.2 Analyst Point of View
  • 14.3 Assumptions and Acronyms

  • 15.1 Primary Data Collection
    • 15.1.1 Steps for Primary Data Collection
      • 15.1.1.1 Identification of KOL
    • 15.1.2 Backward Integration
    • 15.1.3 Forward Integration
    • 15.1.4 How Primary Research Help Us
    • 15.1.5 Modes of Primary Research
  • 15.2 Secondary Research
    • 15.2.1 How Secondary Research Help Us
    • 15.2.2 Sources of Secondary Research
  • 15.3 Data Validation
    • 15.3.1 Data Triangulation
    • 15.3.2 Top Down & Bottom Up Approach
    • 15.3.3 Cross check KOL Responses with Secondary Data
  • 15.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Breast Cancer Liquid Biopsy Market Analysis Market analysis.

01

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

02

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

03

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

04

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

05

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics
Data Points Validated 10,400+
Expert Interviews 54
Countries Covered 39+
Company Profiles 21+
Forecast Accuracy (Historical) 94.2%
Report Pages 250+
Analytical Coverage
Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Latest News about Breast Cancer Liquid Biopsy Market

Sources from Medical Devices & Consumables Industry

How We Serve You

The Three Pillars of End-to-End Market Research Services

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Breast Cancer Liquid Biopsy Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the breast cancer liquid biopsy market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included
  • Buyer intent & sentiment analysis
  • Purchase cycle mapping
  • Price sensitivity research
  • Channel preference profiling
  • Competitive perception study
Most Requested
Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included
  • Ready syndicate report (250+ pages)
  • Custom data scope & segmentation
  • Excel quantitative models
  • Board-ready PPT with key findings
  • Secure cloud portal access
Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included
  • Dedicated analyst assigned to you
  • Live walkthrough of findings
  • Strategic Q&A sessions
  • Go-to-market recommendations
  • NDA-protected engagement

Customize This Report

Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.